Power Law company profile

Molecular Partners

Biotech & Life Sciences · Zurich, Switzerland · Founded 2004 · IPO 2014 Thoroughbred

Develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments

Valuation

$39M

Market cap · May/2026

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

7 investors on Molecular Partners's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Endeavour Vision

BB Biotech Ventures

Johnson & Johnson

Index Ventures

Series B+ 3 investors entered at this stage

Essex Woodlands Health Ventures

EW Healthcare Partners

University of Zürich

Global footprint

Where Molecular Partners has talent and traffic

AI talent share

1.3% of workforce is AI talent
(2 of 153 staff)

Core AI00%

Other AI21.31%

Non-AI workforce15198.69%

Workforce by country

8 countries with
team presence

🇨🇭 Switzerland92.7%

🇩🇪 Germany1.6%

🇳🇱 Netherlands1.6%

🇵🇱 Poland0.8%

🇫🇷 France0.8%

Top 5 of 8 shown

Web traffic by country

8.4K monthly visits
across markets

🇺🇸 United States36.9%

🇨🇭 Switzerland29.8%

🇮🇳 India11.9%

🇩🇪 Germany10.7%

🇬🇧 United Kingdom6%

Top 5 markets shown

Market sentiment

What the market is saying about Molecular Partners

An AI-synthesized read of the highest-engagement posts about Molecular Partners on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Molecular Partners on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles